TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06264427

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Description: Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAGUS
Description: To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NightOwl
Description: Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
Study: NCT05458765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir alafenamide
Description: 200mg/25mg tablet, once daily dosing for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: 200mg/300mg tablet, once daily dosing for 24 weeks
Study: NCT05161533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06427200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Iron
Description: oral iron once daily during or after meals as add-on therapy for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: lactoferrin twice daily before meals as add-on therapy for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactoferrin and oral iron
Description: lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
Study: NCT04770389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib 5mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib 5mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT06335095

Intervention type: OTHER
Intervention: Kinematic sensors
Description: Comparative analysis of kinematic data acquired in supervised and unsupervised environment

Intervention type: OTHER
Intervention: Kinematic sensors
Description: Comparative analysis of kinematic data acquired in supervised and unsupervised environment
Study: NCT05248568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core training
Description: Core training lasts for 12 weeks, three times a week, one hour each time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core training
Description: Core training lasts for 12 weeks, three times a week, one hour each time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core training
Description: Core training lasts for 12 weeks, three times a week, one hour each time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core training
Description: Core training lasts for 12 weeks, three times a week, one hour each time
Study: NCT05645874

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
Study: NCT05517395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health nutrition education
Description: The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
Study: NCT06226350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Description: F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
Study: NCT05273034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1-hour sepsis bundle
Description: The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~* usual test and treatment~* blood culture~* lactate measurement~* broad spectrum antibiotics~* In case of hypotension or lactate \> 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~* In case of initial elevated lactate (\> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation.
Study: NCT04455763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF
Description: Adipose-derived stromal vascular fraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Thumb brace (Actimove® Rhizo Forte)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Thumb brace (Actimove® Rhizo Forte)
Study: NCT05964374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
Study: NCT04549870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast
Description: Treatment according to national roflumilast guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Treatment according to national roflumilast guidelines
Study: NCT04777136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit and comprehensive geriatric assessment
Description: Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group, no designated follow up
Description: Only follow-up on patients own initiative with contact to the general practitioner
Study: NCT05602038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus laborum block
Description: quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus laborum block
Description: quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal bupivacaine
Description: intrathecal bupivacaine 0.5% 15mg and fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine
Description: intrathecal bupivacaine 0.5% 15mg and fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine
Description: intrathecal bupivacaine 0.5% 15mg and fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine
Description: intrathecal bupivacaine 0.5% 15mg and fentanyl
Study: NCT06497348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder
Description: They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder
Description: They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
Study: NCT04591275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB807 Injection
Description: mAb targeting RANKL, human monoclonal antibody targeting RANKL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: mAb targeting RANKL, human monoclonal antibody targeting RANKL
Study: NCT00013208

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Case Management
Study: NCT04841421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-CD147
Description: The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-CD147
Description: The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-CD147
Description: The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
Study: NCT05166629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eatable Alphabet
Description: Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Please see above description of usual care.
Study: NCT06396078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1000 MG
Description: Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)

Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin 2 GM Injection
Description: Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin 250 MG
Description: Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)

Intervention type: DRUG
Group type: OTHER
Intervention: Erythromycin
Description: Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
Study: NCT05442099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iso-principle music playlist
Description: Participants listen to the iso-principle music playlist for 30 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Generic calm music playlist
Description: Participants listen to the calm music playlist for 30 minutes.
Study: NCT06354114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2011
Description: IV infusion, 260 mg/m\^2
Study: NCT05901493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual category training
Description: Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
Study: NCT05422560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the inferior mesenteric artery
Description: The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure.
Study: NCT05534425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GenX intergenerational mentoring program
Description: GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GenX intergenerational mentoring program
Description: GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
Study: NCT06199609

Intervention type: PROCEDURE
Intervention: Hemodialysis pathway
Description: AVF and TCC are two different vascular pathways for hemodialysis

Intervention type: PROCEDURE
Intervention: AVF
Description: Left atrial changes caused by AVF establishment

Intervention type: PROCEDURE
Intervention: AVF
Description: Left atrial changes caused by AVF establishment

Intervention type: PROCEDURE
Intervention: AVF
Description: New onset atrial fibrillation caused by AVF establishment
Study: NCT02014350

Intervention type: DEVICE
Intervention: DePuy Delta Xtend Reverse TSA
Study: NCT05988450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ-Kyrin Transcatheter Mitral Valve Repair System
Description: Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
Study: NCT04701138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SPM Active
Description: Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
Study: NCT05549700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
Study: NCT04758442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional blood sample
Description: Included subjects will provided three blood samples to follow vancomycin concentration
Study: NCT04957576

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Visuo-tactile stimulation
Description: The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-tactile stimulation
Description: The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
Study: NCT04856787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701、 BP102 、XELOX
Description: Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701、 BP102 、XELOX
Description: Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo、 BP102、 XELOX
Description: Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days